{"ORPHApacket":[{"ORPHApacketID":"165","date":"2019-07-19 08:27:55","version":"1.2.11 \/ 4.1.6 [2018-04-12] (orientdb version)","copyright":"Orphanet (c) 2019","ORPHA":"165","Name":[{"lang":"en","label":"Neutral lipid storage disease"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_165","DisorderType":[{"Name":[{"lang":"en","label":"Group of phenomes"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_377794"}],"SubClassOfList":[{"Disorder":[{"Name":[{"lang":"en","label":"Muscular lipidosis"}],"ORPHA":"206953","PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_206953"},{"Name":[{"lang":"en","label":"Disorder of phospholipids, sphingolipids and fatty acids biosynthesis with skeletal muscle predominant involvement"}],"ORPHA":"352312","PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_352312"}]}],"TextSection":[{"Name":[{"lang":"en","label":"Disease definition"}],"Contents":"Neutral lipid storage disease (NLSD) refers to a group of diseases characterized by a deficit in the degradation of cytoplasmic triglycerides and their accumulation in cytoplasmic lipid vacuoles in most tissues of the body. The group is heterogeneous: currently cases of NLSD with icthyosis (NLSDI\/Dorfman-Chanarin disease; see this term) and NLSD with myopathy (NLSDM\/neutral lipid storage myopathy; see this term) can be distinguished."}],"AverageAgeOfOnsetList":[{"count":"2","AverageAgeOfOnset":[{"Name":[{"lang":"en","label":"Infancy"}]},{"Name":[{"lang":"en","label":"Neonatal"}]}]}],"TypeOfInheritanceList":[{"count":"1","TypeOfInheritance":[{"Name":[{"lang":"en","label":"Autosomal recessive"}]}]}],"SynonymList":[{"count":"1","Synonym":[{"lang":"en","label":"Lipidosis with triglyceride storage disease"}]}]}]}